# US 12,178,871 B2 · Complex for enhancing immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,871 B2
- Document ID: US12178871B2
- Status: Granted
- Kind: B2
- Application number: 17/256,979
- Filed: 2019-06-28
- Published: 2022-03-10
- Granted: 2024-12-31
- Earliest claimed: 2018-06-29
- Assignees: Beijing Yisheng Biotechnology Co., Ltd.
- Applicants: Xinfu (Beijing) Medical Technology Co., Ltd.
- Inventors: Haixiang Lin; Fang Liu; Li Zha
- Web page: https://patentgrep.com/patent/US12178871B2

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/0043: {Nose}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/787: containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A novel composite, and research on the preparation, application and the like of the composite. The method for preparing the composite comprises: contacting a polyinosinic-polycytidylic acid, at least one cationic stabilizer, and a soluble calcium salt in a liquid reaction system, the cationic stabilizer being a water-soluble non-antibiotic amino compound having a molecular weight of less than or equal to 5 kDa, or a graft copolymer formed by a water-soluble non-antibiotic amino compound and one or more of methoxypolyethylene glycol, polyethylene glycol, polyethylenimine, folic acid, or galactose. The composite has moderate viscosity and molecular weight, is convenient to use in pharmaceutical application, has stable chemical properties, is not easy to be degraded in long-term storage, and is safe to use. The composite, if used alone, can significantly enhance the non-specific immune response of the body and achieve the purpose of preventing and treating diseases, and other drugs, and can achieve better anti-tumor, anti-viral and anti-(super) bacteria efficacy and is easily absorbed by patients, if used in combination with other drugs.

## Claims

### Claim 1

A combination product for potentiating an immune response, comprising a polyinosinic-polycytidylic acid having a molecular weight of 100 bp-3000 bp and having been heated at 80° C.-99° C. for 70 minutes-120 minutes, at least a cationic stabilizer, and a soluble calcium salt in a liquid reaction system;
wherein the cationic stabilizer is a graft formed by a chitosan oligosaccharide and methoxypolyethylene glycol, a mass ratio of the polyinosinic-polycytidylic acid to the cationic stabilizer is 1:0.8˜25.6, and the graft has a molecular weight of less than or equal to 50 kDa; or
wherein the cationic stabilizer comprises chitosan oligosaccharide and a mass ratio of the polyinosinic-polycytidylic acid:chitosan oligosaccharide is 1:0.4˜ 0.8 or the cationic stabilizer comprises a combination of chitosan oligosaccharide and polyethyleneimine, and a mass ratio of the polyinosinic-polycytidylic acid:chitosan oligosaccharide:polyethyleneimine is 1:0.8˜6.4:32.

### Claim 2 (depends on 1)

A complex for potentiating an immune response, prepared from reagents in the combination product of claim 1.

### Claim 3 (depends on 2)

The complex according to claim 2, wherein preparation is carried out in a solution system, and in the reagents, the polyinosinic-polycytidylic acid has a concentration of 0.1 mg/ml˜10 mg/ml.

### Claim 4 (depends on 2)

The complex according to claim 2, wherein, the complex is stored in a solution;
wherein, the solution is a buffer solution;
wherein, the solution has a pH in a range of 5.0˜7.2.

### Claim 5 (depends on 2)

A pharmaceutical composition comprising the complex according to claim 2, wherein the pharmaceutical composition further comprises one or more of an immune cell therapy drug, an antibody therapy drug, a chemical drug, a substance that promotes mucosal immune absorption or mucosal adhesion, an immunomodulator, a pathogen antigen, a pattern recognition receptor ligand, and a pharmaceutically acceptable salt or excipient.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the immune cell therapy drug is one or more selected from the group consisting of tumor infiltrating lymphocytes (TILs), dendritic cells (DCs), cytokine induced killer cells (CIKs), dendritic cells-cytokine induced killer cells (DCs-CIKs), natural killer cells (NKs), γδT cells, CD3AK, CAR-T and TCR-T;
wherein, the antibody therapy drug is selected from the group consisting of an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA4 antibody and an anti-CD antigen antibody;
wherein the chemical drug is one or more selected from the group consisting of an alkylating agent, an antimetabolity, an antitumor antibiotic, a plant antitumor drug, a hormone drug and a miscellaneous drug;
wherein the miscellaneous drug is selected from the group consisting of L-asparaginase, cisplatin, carboplatin, oxaliplatin, dacarbazine, hexamethylmelamine drugs, and derivatives of aforementioned drugs;
wherein the substance that promotes mucosal immune absorption or mucosal adhesion is one or more selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, nonionic surfactants, special surfactants, chelating agents, adhesives, polylactic acid-glycolic acid copolymers, dextrans, and polysaccharides;
wherein the immunomodulator is one or more selected from the group consisting of cytokines, chemokines, stem cell growth factors, lymphotoxins, hematopoietic factors, colony stimulating factors (CSFs), interferons, erythropoietins, thrombopoietins, tumor necrosis factors (TNFs), interleukins (ILs), granulocyte-colony stimulating factors (G-CSFs), granulocyte macrophage-colony stimulating factors (GM-CSFs) and stem cell growth factors;
wherein the pathogen antigen is selected from the group consisting of a tumor, a virus, a bacterium, a fungus or a parasite antigen; and
wherein the pattern recognition receptor-ligand is selected from the group consisting of a RLR receptor-ligand, a CLR receptor-ligand, and a NLR receptor-ligand.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6,
wherein the tumor includes those arising from any lesions in bone, bone connection, muscle, lung, trachea, pharynx, nose, heart, spleen, artery, vein, blood, capillary, lymph node, lymphatic vessel, lymphatic fluid, oral cavity, pharynx, esophagus, stomach, duodenum, small intestine, colon, rectum, anus, appendix, liver, gallbladder, pancreas, parotid gland, sublingual gland, urinary kidney, ureter, bladder, urethra, ovary, fallopian tube, uterus, vagina, vulva, scrotum, testes, vas deferens, penis, eyes, ears, nose, tongue, skin, brain, brainstem, medulla oblongata, spinal cord, cerebro-spinal fluid, nerves, thyroid, parathyroid gland, adrenal gland, pituitary gland, pineal gland, pancreatic islet, thymus, gonad, sublingual gland, and parotid gland;
wherein, the bacterium includes one or more of Staphylococcus, Streptococcus, Listeria, Erysipelothrix, Renibacterium, Bacillus, Clostridium, Mycobacterium, Actinomyces, Nocardia, Corynebacterium, Rhodococcus, Bacillus anthracis, erysipelas bacillus, Bacillus tetani, Listeria monocytogenes, Bacillus perfringens, Bacillus gangraenae emphysematosae, tuberculosis, Escherichia coli, Bacterium proteus, Shigella dysenteriae, Pneumobacillus, Bacterium burgeri, Clostridium perfringens, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Acinetobacter, Yersinia, Legionella pneumophila, Bordetella pertussis, Bordetella parapertussis, Shigella, Pasteurella, Vibrio cholerae, and Vibrio Parahemolyticus;
wherein, the parasite includes one or more of parasites in the digestive tract, intraluminal parasites, intrahepatic parasites, intrapulmonary parasites, brain tissue parasites, intravascular parasites, intralymphatic parasites, muscle tissue parasites, intracellular parasites, bone tissue parasites, and intraocular parasites;
wherein, the virus includes one or more of adeniviridae, arenaviridae, astroviridae, bunyaviridae, cliciviridae, flaviviridae, hepatitis delta virus, hepeviridae, mononegavirales, nidovirales, piconaviridae, orthomyxoviridae, papillomaviridae, parvoviridae, polyomaviridae, poxviridae, reoviridae, retroviridae or togaviridae;
wherein, the fungus includes one or more of Coccidioides immitis, Coccidioides posadasii, Histoplasma capsulatum, Histoplasma duboisii, Blastomyces lobo, Paracoccidioides brasiliensis, Blastomyces dermatitis, Sporothrix schenckii, Penicillium marneffei, Candida albicans, Candida glabrata, Candida tropicalis, Candida lusitaniae, Pneumocystis carinii, Aspergillus, Exophiala jeanselmei, Fonsecaea Pedrosoi, Fonsecaea compacta, Chromomyces verruciformis, Pigmentation dermatitis, Geotrichum candidum, Pseudallescheria boydii, Cryptococcus neoformans, Trichosporon Cutaneum, Rhizopus oryzae, Mucor indicus, Absidia corymbifera, Syncephalastrum racemosum, Basidiobolus ranarum, Conidiobolus coronatus, Conidiobolus incongruus, Enterocytozoon bieneusi, Encephalitozoon intestinalis, Rhinosporidium seeberi, hyalohyphomycet, and phaeohyphomycete.

### Claim 8 (depends on 1)

The combination product according to claim 1, wherein the chitosan oligosaccharide has a molecular weight of less than or equal to 3200 Da, and polyethyleneimine has a molecular weight of less than or equal to 40,000 Da.

### Claim 9 (depends on 1)

The combination product according to claim 1, wherein the chitosan oligosaccharide has a degree of deacetylation that is greater than or equal to 70%.

### Claim 10 (depends on 1)

The combination product according to claim 1, wherein the soluble calcium salt is CaCl2) and/or Ca(NO3)2.

### Claim 11 (depends on 1)

The combination product according to claim 1, wherein the polyinosinic-polycytidylic acid has a molecular weight of 100 bp-1500 bp.

### Claim 12 (depends on 1)

The combination product according to claim 1, wherein the combination product further comprises one or more of a pH adjuster, sodium tripolyphosphate, sodium alginate, phenylboronic acid, catechol, buffer salt/reagent, and water.

### Claim 13 (depends on 2)

The complex according to claim 2, wherein the concentration of the cationic stabilizer is 0.8 mg/ml˜25.6 mg/ml.

### Claim 14 (depends on 2)

The complex according to claim 2, wherein preparation is carried out in a solution system, and in the reagents, a concentration of calcium ions in the soluble calcium salt is 0.1 mM˜1 mM.

### Claim 15 (depends on 2)

The complex according to claim 2, wherein the concentration of the polyinosinic-polycytidylic acid is 0.5 mg/ml˜5 mg/ml.